Logo image of TOVX

THERIVA BIOLOGICS INC (TOVX) Stock Fundamental Analysis

USA - NYSEARCA:TOVX - US87164U5083 - Common Stock

0.4599 USD
+0.01 (+2.73%)
Last: 10/9/2025, 9:36:02 AM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to TOVX. TOVX was compared to 536 industry peers in the Biotechnology industry. TOVX has a bad profitability rating. Also its financial health evaluation is rather negative. TOVX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TOVX has reported negative net income.
In the past year TOVX has reported a negative cash flow from operations.
In the past 5 years TOVX always reported negative net income.
In the past 5 years TOVX always reported negative operating cash flow.
TOVX Yearly Net Income VS EBIT VS OCF VS FCFTOVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

TOVX's Return On Assets of -82.49% is on the low side compared to the rest of the industry. TOVX is outperformed by 70.34% of its industry peers.
TOVX has a Return On Equity of -278.22%. This is in the lower half of the industry: TOVX underperforms 70.15% of its industry peers.
Industry RankSector Rank
ROA -82.49%
ROE -278.22%
ROIC N/A
ROA(3y)-44.56%
ROA(5y)-63.19%
ROE(3y)-72.49%
ROE(5y)-81.87%
ROIC(3y)N/A
ROIC(5y)N/A
TOVX Yearly ROA, ROE, ROICTOVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

TOVX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TOVX Yearly Profit, Operating, Gross MarginsTOVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, TOVX has less shares outstanding
The number of shares outstanding for TOVX has been increased compared to 5 years ago.
Compared to 1 year ago, TOVX has a worse debt to assets ratio.
TOVX Yearly Shares OutstandingTOVX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
TOVX Yearly Total Debt VS Total AssetsTOVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -16.09, we must say that TOVX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of TOVX (-16.09) is worse than 81.90% of its industry peers.
A Debt/Equity ratio of 0.15 indicates that TOVX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.15, TOVX is doing worse than 66.04% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z -16.09
ROIC/WACCN/A
WACCN/A
TOVX Yearly LT Debt VS Equity VS FCFTOVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 1.19 indicates that TOVX should not have too much problems paying its short term obligations.
The Current ratio of TOVX (1.19) is worse than 85.82% of its industry peers.
TOVX has a Quick Ratio of 1.19. This is a normal value and indicates that TOVX is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.19, TOVX is not doing good in the industry: 85.26% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.19
Quick Ratio 1.19
TOVX Yearly Current Assets VS Current LiabilitesTOVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

TOVX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.07%.
EPS 1Y (TTM)-3.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TOVX will show a very strong growth in Earnings Per Share. The EPS will grow by 23.40% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y76.93%
EPS Next 2Y36.51%
EPS Next 3Y23.4%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TOVX Yearly Revenue VS EstimatesTOVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 100M 200M 300M
TOVX Yearly EPS VS EstimatesTOVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -1K -2K -3K -4K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TOVX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TOVX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TOVX Price Earnings VS Forward Price EarningsTOVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TOVX Per share dataTOVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as TOVX's earnings are expected to grow with 23.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.51%
EPS Next 3Y23.4%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TOVX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERIVA BIOLOGICS INC

NYSEARCA:TOVX (10/9/2025, 9:36:02 AM)

0.4599

+0.01 (+2.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/bmo
Earnings (Next)11-10 2025-11-10
Inst Owners8.25%
Inst Owner Change0%
Ins Owners0.14%
Ins Owner Change0%
Market Cap4.42M
Analysts80
Price Target7.14 (1452.51%)
Short Float %3.46%
Short Ratio0.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.33%
Min EPS beat(2)38.93%
Max EPS beat(2)63.73%
EPS beat(4)3
Avg EPS beat(4)36.25%
Min EPS beat(4)-6.82%
Max EPS beat(4)63.73%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.42
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-12.23
EYN/A
EPS(NY)-3.33
Fwd EYN/A
FCF(TTM)-1.88
FCFYN/A
OCF(TTM)-1.88
OCFYN/A
SpS0
BVpS1.11
TBVpS-0.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -82.49%
ROE -278.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.56%
ROA(5y)-63.19%
ROE(3y)-72.49%
ROE(5y)-81.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.16%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.19
Quick Ratio 1.19
Altman-Z -16.09
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)94.56%
Cap/Depr(5y)59.96%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.96%
EPS Next Y76.93%
EPS Next 2Y36.51%
EPS Next 3Y23.4%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-34.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.46%
OCF growth 3YN/A
OCF growth 5YN/A